Ralliant (NYSE:RAL) SVP Buys $99,942.15 in Stock

Ralliant Corporation (NYSE:RAL) SVP Amir Kazmi acquired 2,545 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was bought at an average cost of $39.27 per share, for a total transaction of $99,942.15. Following the purchase, the senior vice president directly owned 39,699 shares of the company’s stock, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ralliant Trading Up 2.9%

Shares of NYSE:RAL opened at $39.50 on Monday. The stock has a 50 day moving average of $51.52 and a 200 day moving average of $46.72. The company has a market cap of $4.46 billion and a PE ratio of 31.10. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analysts’ expectations of $543.04 million. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, March 9th. Ralliant’s dividend payout ratio is presently 15.75%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Citigroup dropped their price objective on Ralliant from $61.00 to $51.00 and set a “buy” rating for the company in a research note on Friday. Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a report on Friday. Royal Bank Of Canada cut their price objective on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday. Oppenheimer cut their target price on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday. Finally, Truist Financial decreased their price target on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.30.

Institutional Trading of Ralliant

A number of large investors have recently made changes to their positions in RAL. Nordea Investment Management AB purchased a new stake in Ralliant in the second quarter valued at about $29,477,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Ralliant during the second quarter worth about $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Ralliant during the second quarter valued at about $1,410,000. JPMorgan Chase & Co. acquired a new position in shares of Ralliant during the second quarter valued at about $18,494,000. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Ralliant by 5,269.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company’s stock valued at $14,000,000 after purchasing an additional 311,134 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.